Table 2 Incidence of common adverse events reported in ⩾20% of patients by maximum NCI CTCAE toxicity grade
All grades | Grades 3/4 | |||
|---|---|---|---|---|
MedDRA preferred term | No patients | % | Number of patients | % |
Any event | 120 | 98.4 | 41 | 33.6 |
Diarrhoea | 86 | 70.5 | 7 | 5.7 |
Rash | 59 | 48.4 | 1 | 0.8 |
Stomatitis | 54 | 44.3 | 0 | 0 |
Nausea | 48 | 39.3 | 1 | 0.8 |
Anorexia | 48 | 39.3 | 10 | 8.2 |
Fatigue | 47 | 38.5 | 4 | 3.3 |
Pruritus | 36 | 29.5 | 0 | 0 |
Nasopharyngitis | 33 | 27.0 | 0 | 0 |
Aspartate aminotransferase increased | 28 | 23.0 | 5 | 4.1 |
Dry skin | 27 | 22.1 | 0 | 0 |
Vomiting | 27 | 22.1 | 2 | 1.6 |
Pyrexia | 24 | 19.7 | 1 | 0.8 |
Weight decreased | 22 | 18.0 | 0 | 0 |
Alanine aminotransferase increased | 21 | 17.2 | 3 | 2.5 |
Blood alkaline phosphatase increased | 20 | 16.4 | 4 | 3.3 |
Dyspnoea | 20 | 16.4 | 2 | 1.6 |
